Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
- Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics
Oxford, UK, 6 November 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), an immunology company tackling the root causes of disease through a revolutionary new approach to solving human genetics, is delighted that its founder, Professor James Davies and his team at the Weatherall Institute of Molecular Medicine, Oxford University have published a paper in Cell. The paper, “Mapping chromatin structure at base-pair resolution unveils a unified model of cis-regulatory element interactions” demonstrates the most detailed view yet of how DNA folds and functions inside living cells. This reveals the intricate structure of the genome which can be used to decode the regulation of gene expression at scale to identify new drug targets.
